Novavax is initiating an initial phase trial for the combined influenza / COVID-19 vaccine

September 8 (Reuters) – Vaccine developer Novavax Inc. (NVAX.O) said on Wednesday it had started an early-stage study to test its combined flu and COVID-19 vaccine.

The trial, which will take place in Australia, will recruit 640 healthy adults between the ages of 50 and 70 who have already been previously infected with the coronavirus or have received an authorized COVID-19 vaccine at least eight weeks before the study. .

Participants will receive a combination of the company’s COVID-19 vaccine candidate, NVX-CoV2373, and their NanoFlu flu vaccine along with an adjuvant or booster vaccine.

“The combination of these two vaccines … can lead to greater efficiency of the health system and achieve high levels of protection against COVID-19 and influenza with a single regimen,” said Gregory Glenn, President of Research and Novavax development. statement.

Novavax had said in May that it expects combined seasonal flu and COVID-19 vaccines to be likely to be key to combating emerging variants of COVID-19. His NanoFlu / NVX-CoV2373 vaccine had elicited robust responses to both influenza A and B and protected against coronavirus in preclinical studies. Read more

Novavax expects test results during the first half of 2022.

Reports from Mrinalika Roy to Bengaluru; Edited by Krishna Chandra Eluri

Our standards: the principles of trust of Thomson Reuters.